Common questions
AHK-Cu — questions, answered plainly.
6 research-context questions about AHK-Cu. Answers stay neutral and reference what is published in the peer-reviewed literature — no dosing, no human-use guidance, no extrapolation beyond what the cited studies report.
- 01
What is AHK-Cu?
AHK-Cu is a copper-binding tripeptide (Ala-His-Lys) often grouped with GHK-Cu in skin and hair research. Direct primary literature on AHK / AHK-Cu is more limited than on GHK-Cu.
- 02
Is AHK-Cu the same as GHK-Cu?
No. The sequence differs by the N-terminal residue: GHK is Gly-His-Lys, AHK is Ala-His-Lys. Both bind Cu(II) at the histidine but have different surrounding chemistry.
- 03
What does the cited research show?
Jung 2018 (Differentiation, PMID 29567599) studied a vitamin-C-conjugated AHK in C2C12 myoblast cells, reporting enhanced osteogenic differentiation via Smad and MAPK pathways. Bar-Or 2001 (Biochem Biophys Res Commun, PMID 11396981) and May 2021 (Molecules, PMID 34063080) describe copper-binding chemistry of the related DAHK serum-albumin N-terminal tetrapeptide.
- 04
Is AHK-Cu used in hair-growth products?
AHK-Cu appears in some cosmetic hair-growth products. The peer-reviewed clinical-trial evidence supporting those product claims is limited compared to the foundational chemistry literature.
- 05
Is AHK-Cu approved as a medicine?
No. AHK-Cu is not approved as a medicine in any jurisdiction. Where it appears commercially it is regulated as a cosmetic ingredient.
- 06
What are the evidence caveats for AHK-Cu?
Primary peer-reviewed AHK / AHK-Cu literature is limited and overlaps with the related DAHK research. Cosmetic claims associated with AHK-Cu products are not supported by a controlled-trial evidence base.
Important
These answers are not medical advice.
AHK-Cu is referenced in research literature only. Palthera does not provide dosage, cycling, stacking, or injection guidance, and content is not intended to support consumer or therapeutic use. Speak to a qualified clinician for any health decisions.